Coronavirus: US approves Drug that Speeds Up Recovery by 30% in Covid-19 Patients

The drug, Remdesivir has been given ’emergency approval’ to treat Covid-19 in the US.


THE US Food and Drug Administration on Friday authorised Remdesivir, an experimental antiviral drug, for emergency use to treat Covid-19.

The authorisation allows the intravenous drug to be distributed to doctors to administer to patients with severe disease, namely patients with low blood oxygen or those needing breathing assistance with a mechanical ventilator.

Many health experts have had high hopes for the drug, which was initially developed by Gilead Sciences to treat Ebola, and it has since been used in experiments to treat the coronaviruses SARS and MERS. That early testing gave Remdesivir a head start in the race for a treatment to Covid-19.

But despite the release of some early study results this week, it’s still not clear how effective the drug is at fighting the virus, and more research is needed before it can be used as the default treatment.

Remdesivir previously showed some success in animal models. Now, early results from a clinical trial at the National Institutes of Health (NIH) show that Covid-19 patients who took Remdesivir recovered 31 per cent faster than those prescribed a placebo. An internal study from Gilead also found that the drug was just as effective over five days of use as it is over 10.

Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told reporters at the White House on April 29 that he thought the findings were significant.

“This is really quite important,” he said. “This will be the standard of care.”

But a randomised trial of the drug in China recently published in the Lancet found that there was no statistical benefit to taking the drug.

Taken together, the studies highlight the need for more studies. Remdesivir may or may not work, but it’s hard to say based on the evidence available at this point.











FacebookTwitterRedditWhatsAppTelegramLinkedInEmailCopy Link
Go Back
Written by

Tony Winterburn

Share your story with us by emailing [email protected], by calling +34 951 38 61 61 or by messaging our Facebook page


    Leave a comment

    Your email address will not be published.